A217730 Stock Overview
Kangstem Biotech Co., Ltd., a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kangstem Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,675.00 |
| 52 Week High | ₩3,485.00 |
| 52 Week Low | ₩1,166.00 |
| Beta | 0.18 |
| 1 Month Change | 41.38% |
| 3 Month Change | 35.10% |
| 1 Year Change | -11.42% |
| 3 Year Change | -60.89% |
| 5 Year Change | -87.35% |
| Change since IPO | -71.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| A217730 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 2.5% | 0.3% | -0.4% |
| 1Y | -11.4% | 5.7% | 4.5% |
Return vs Industry: A217730 underperformed the KR Biotechs industry which returned 5.7% over the past year.
Return vs Market: A217730 underperformed the KR Market which returned 4.5% over the past year.
Price Volatility
| A217730 volatility | |
|---|---|
| A217730 Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A217730's share price has been volatile over the past 3 months.
Volatility Over Time: A217730's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 115 | Jong-Cheon Na | www.kangstem.com |
Kangstem Biotech Co., Ltd., a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn’s disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors, as well as growth and differentiation factor 11, and Fibroblast growth factor 2 for skin growth and regeneration.
Kangstem Biotech Co., Ltd. Fundamentals Summary
| A217730 fundamental statistics | |
|---|---|
| Market cap | ₩149.63b |
| Earnings (TTM) | -₩21.95b |
| Revenue (TTM) | ₩12.70b |
11.8x
P/S Ratio-6.8x
P/E RatioIs A217730 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A217730 income statement (TTM) | |
|---|---|
| Revenue | ₩12.70b |
| Cost of Revenue | ₩11.06b |
| Gross Profit | ₩1.64b |
| Other Expenses | ₩23.59b |
| Earnings | -₩21.95b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -392.38 |
| Gross Margin | 12.93% |
| Net Profit Margin | -172.77% |
| Debt/Equity Ratio | 23.0% |
How did A217730 perform over the long term?
See historical performance and comparison